Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Complications of Patent Foramen Ovale and Atrial Septal Defect Closure Devices

Complications of Patent Foramen Ovale and Atrial Septal Defect Closure Devices Atrial septal defect (ASD) is a common congenital defect seen in 1 in 1,000 live births, and represents 40% of all acyanotic shunts in adults. Patent foramen ovale (PFO) is much more common and is present in 25% of adults. It is likely that many cryptogenic strokes, which account for 40% of all strokes, are related to PFO. Other clinical syndromes associated with PFO include platypnea‐orthodeoxia, decompression sickness, and possibly migraine headache. As such, ASDs and PFOs represent significant health burdens. Until recently, surgery was the only therapeutic option for ASD closure, and anticoagulation therapy was the preferred initial choice of treatment for patients with PFO‐related stroke. Surgical ASD closure is associated with low mortality and morbidity rates; in fact, it is one of the lowest risk cardiac surgical procedures. Despite the low risk, it remains a surgical procedure requiring cardiopulmonary bypass, prolonged recovery, and a scar which is cosmetically displeasing to many young patients. Prolonged anticoagulant therapy in PFO patients can be inconvenient for the elderly and intolerable in the active young. Additionally, the recurrent stroke and transient ischemic attack (TIA) rates are not inconsequential. These shortcomings provided the impetus to devise new therapeutic options for these http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Interventional Cardiology Wiley

Complications of Patent Foramen Ovale and Atrial Septal Defect Closure Devices

Download PDF
3 pages

Loading next page...
 
/lp/wiley/complications-of-patent-foramen-ovale-and-atrial-septal-defect-closure-YqMiTBeo3Y

References (22)

Publisher
Wiley
Copyright
Copyright © 2006 Wiley Subscription Services, Inc., A Wiley Company
ISSN
0896-4327
eISSN
1540-8183
DOI
10.1111/j.1540-8183.2006.00126.x
pmid
16650245
Publisher site
See Article on Publisher Site

Abstract

Atrial septal defect (ASD) is a common congenital defect seen in 1 in 1,000 live births, and represents 40% of all acyanotic shunts in adults. Patent foramen ovale (PFO) is much more common and is present in 25% of adults. It is likely that many cryptogenic strokes, which account for 40% of all strokes, are related to PFO. Other clinical syndromes associated with PFO include platypnea‐orthodeoxia, decompression sickness, and possibly migraine headache. As such, ASDs and PFOs represent significant health burdens. Until recently, surgery was the only therapeutic option for ASD closure, and anticoagulation therapy was the preferred initial choice of treatment for patients with PFO‐related stroke. Surgical ASD closure is associated with low mortality and morbidity rates; in fact, it is one of the lowest risk cardiac surgical procedures. Despite the low risk, it remains a surgical procedure requiring cardiopulmonary bypass, prolonged recovery, and a scar which is cosmetically displeasing to many young patients. Prolonged anticoagulant therapy in PFO patients can be inconvenient for the elderly and intolerable in the active young. Additionally, the recurrent stroke and transient ischemic attack (TIA) rates are not inconsequential. These shortcomings provided the impetus to devise new therapeutic options for these

Journal

Journal of Interventional Cardiology – Wiley

Published: Apr 1, 2006

There are no references for this article.